Substance
ID:4513
Names and Identifiers
Brand Name
Raplon
IUPAC Traditional name
1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5-(acetyloxy)-2,15-dimethyl-4-(piperidin-1-yl)-14-(propanoyloxy)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl]-1-(prop-2-en-1-yl)piperidin-1-ium bromide
Synonyms
RapacuroniumRapacuronium bromide
IUPAC name
1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5-(acetyloxy)-2,15-dimethyl-4-(piperidin-1-yl)-14-(propanoyloxy)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl]-1-(prop-2-en-1-yl)piperidin-1-ium bromide
Properties
No Data Available
Click here to submit data
Molecule Details
Drug Groups
withdrawn
Description
Rapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm.
Indication
Used in anaesthesia, to aid and enable endotracheal intubation.
Pharmacology
Rapacuronium is a rapidly acting, non-depolarizing neuromuscular blocker.
Affected Organisms
Humans and other mammals
Biotransformation
Hydrolyzed to active metabolites (Cytochrome P450 system is not involved).
Half Life
141 minutes (mean)
Protein Binding
Variable. Plasma protein binding of rapacuronium was studied in vitro for human plasma by equilibrium dialysis. The protein binding was variable and ranged between 50% and 88%, which was at least partly due to hydrolysis of rapacuronium bromide to its 3-hydroxy metabolite. The specific plasma protein to which rapacuronium binds is unknown. Plasma protein binding of the 3-hydroxy metabolite was not determined.
External Links
•
[RxList]
Molecular Spectra
No Data Available
Click here to submit data
References
No Data Available
Click here to submit data